Unlock instant, AI-driven research and patent intelligence for your innovation.

Vitamin D receptor agonists to treat diseases involving CXCL12 activity

An agonist, vitamin technology, applied in metabolic diseases, organic active ingredients, respiratory diseases, etc., can solve the problem of unclear cytokines and molecular pathways

Inactive Publication Date: 2016-03-30
SALK INST FOR BIOLOGICAL STUDIES
View PDF8 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the cytokines and molecular pathways that control this approach are not well understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vitamin D receptor agonists to treat diseases involving CXCL12 activity
  • Vitamin D receptor agonists to treat diseases involving CXCL12 activity
  • Vitamin D receptor agonists to treat diseases involving CXCL12 activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0144] experimental method

[0145] cell line

[0146] The human pancreatic cancer cell lines MiaPaCa-2 (CRL-1420), BxPC-3 (CRL-1687), HPAC (CRL-2119), Pancl (CRL-1469) and AsPCl (CRL-1682) were obtained from ATCC, and Culture according to provider's directions. The mouse pancreatic cancer cell lines p532.1.1, p534.4 and Ink2.2 were derived from PDA in the following mice: LSL-Kras G12D / + ; Trp53 lox / lox ; Pdxl-Cre mice or LSL-Kras G12D ; Ink4a / Arf lox / lox ; Pdxl-Cre mice (Bardeesy et al., 2006; Collisson et al., 2011), and cultured as previously described (Collisson et al., 2011; Collisson et al., 2012). Spontaneously immortalized human pancreatic stellate cell line hPSCs were isolated and established from pancreatic cancer patients after surgical resection as previously described (Mantoni et al., 2011).

[0147] Isolation and Culture of Primary Pancreatic Stellate Cells

[0148] Mouse PSC Isolation

[0149] Pancreatic stellate cells (PSCs) were isolated from the pan...

Embodiment 2

[0215] Identification of cancer-associated gene signatures in PSCs

[0216]To characterize cancer-associated changes in PSCs, massively parallel sequencing (RNA-Seq) of PSC transcriptomes was performed at various stages of activation. Progressive activation of cultured primary PSCs (Omary et al., 2007) is capitalized, and pre-activated (3-day culture) and activated (7-day culture) PSCs isolated from healthy mouse pancreas were analyzed for transcription Group( Figure 1A and Figures 2A to 2C ). This analysis revealed that during activation, PSCs decreased the expression of genes involved in lipid storage and lipid metabolism, consistent with the loss of the lipid droplet phenotype associated with quiescent phase. Activation also results in elevated expression of a range of genes previously associated with tumor supportive potential, including cytokines, growth factors, ECM components and signaling molecules such as Wnts. Concurrent induction of inflammatory genes is of pa...

Embodiment 3

[0219] VDR regulates the PSC activation network

[0220] These analyzes also revealed that PSCs unexpectedly express high levels of the vitamin D receptor (VDR), which was previously thought not to be expressed in the exocrine pancreas (Zeitz et al., 2003)( Figure 1D , 1E , 2D and 2E). VDR expression is maintained in cancer-associated PSCs ( Figure 1F ). Whereas previous work has shown VDR as a key regulator of fibrogenesis gene networks in closely related hepatic stellate cells (Ding et al., 2013), and since l,25(OH) 2 D. 3 This pharmaceutically acceptable receptor was examined for the established anti-inflammatory (Cantorna et al., 1996, 1998; Cantorna et al., 2000; Ma et al., 2006; Nagpal et al., 2005; Deeb et al., 2007) effects of its analogues. Closely related to this study is the strong inverse association of plasma vitamin D levels with pancreatic cancer risk (Wolpin et al., 2012), a relationship that remains unexplained. Furthermore, vitamin D insufficiency has...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

Provided herein are methods of treating and preventing pancreatitis, such as pancreatitis induced by glucagon- like peptide (GLP) agonists (such as GLP-1 agonists, for example Byetta<TM>), by administration of a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors). In some examples the subject has diabetes, such as type 2 diabetes.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Provisional Application No. 61 / 831,515, filed June 5, 2013, which is incorporated herein by reference in its entirety. [0003] Confirmation of government support [0004] This invention was made with government support under grants HL105278, DK0577978, DK090962, CA014195, and ES010337 from the National Institutes of Health and T32-CA009370 from the National Research Foundation. The government has certain rights in this invention. technical field [0005] The present application relates to methods of treating or preventing diseases such as pancreatitis and cancer in which there is activation of juxtaposed astrocytes by administering one or more vitamin D receptor (VDR) agonists. [0006] Confirmation of government support [0007] This invention was made with government support under grants T32-CA009370 from the National Research Foundation and HL105278, DK0577978, DK090962, CA01...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P3/14A61P3/08A61P5/48A61P35/00A61P1/18A61K31/592
CPCA61K31/592A61K45/06A61K31/517A61K31/7068A61K9/0019A61K31/424A61K31/43A61K31/496A61K31/513A61K47/62A61K47/6849A61K31/593A61P1/16A61P1/18A61P11/00A61P13/08A61P13/12A61P3/14A61P35/00A61P3/08A61P43/00A61P5/48A61P3/10A61K2300/00
Inventor M·谢尔曼M·道恩斯R·M·埃文斯
Owner SALK INST FOR BIOLOGICAL STUDIES